ERIS LIFESCIENCES share price has zoomed 5% and is presently trading at Rs 1,366.5.
Meanwhile, the BSE HEALTHCARE index is at 42,943.0 (up 0.5%).
Among the top gainers in the BSE HEALTHCARE index today are SUVEN PHARMACEUTICALS (up 1.2%) and Biocon (up 1.1%).
Procter & Gamble Health (down 1.2%) and ALEMBIC PHARMA (down 0.8%) are among the top losers today.
Over the last one year, ERIS LIFESCIENCES has moved up from Rs 800.3 to Rs 1,366.5, registering a gain of Rs 566.3 (up 70.8%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,859.6 to 42,943.0, registering a gain of 54.1% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 136.4%), Glenmark Pharma (up 122.7%) and SUVEN PHARMACEUTICALS (up 108.2%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,826.9 (up 0.1%).
The top gainers among the BSE Sensex today are Sun Pharma (up 0.6%) and Hindustan Unilever (up 0.5%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 25,054.3 . Cipla and Bajaj Auto are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,996.6 to 81,826.9, registering a gain of 16,830.3 points (up 25.9%).
ERIS LIFESCIENCES net profit fell 4.5% YoY to Rs 894 million for the quarter ended June 2024, compared to a profit of Rs 937 million a year ago. Net sales rose 54.2% to Rs 7,197 million during the period as against Rs 4,666 million in April-June 2023.
For the year ended March 2023, ERIS LIFESCIENCES reported 7.8% decrease in net profit to Rs 3,742 million compared to net profit of Rs 4,058 million during FY22. Revenue of the company grew 25.1% to Rs 16,851 million during FY23.
The current Price to earnings ratio of ERIS LIFESCIENCES, based on rolling 12 month earnings, stands at 47.3.
Equitymaster requests your view! Post a comment on "ERIS LIFESCIENCES Gains 5%; BSE HEALTHCARE Index Up 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!